JPMorgan Starts GW Pharma (GWPH) at Overweight

JPMorgan analyst Cory Kasimov initiates coverage on GW Pharma (NASDAQ: GWPH) with a Overweight rating and a price target of $134.00.

The analyst says the company is a clear leader in the cannabinoid science.drug development field. He believes Epidiolex is poised for a solid launch in approved indications.

For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.

Shares of GW Pharma closed at $97.39 yesterday.

You May Also Be Interested In

• William Blair Starts First Advantage (FA) at Outperform, 'Best-in-Class Background Screener'
• Costco Wholesale (COST) PT Raised to $710 at Citi
• Lake Street Capital Markets Starts Research Solutions Inc. (RSSS) at Buy